Financial Instruments and Fair Value Measurements (Tables)

9 Months Ended

Sep. 28, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

	September 28, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.3	$	24.5	$	10.8	$	—
Equity securities	—		—		—		—
Foreign exchange forward and option contracts	—		—		—		—
	$	35.3	$	24.5	$	10.8	$	—
Liabilities:
Deferred compensation liabilities	$	41.7	$	—	$	41.7	$	—
Contingent consideration and acquired contingent liabilities	167.3		—		—		167.3
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	209.1	$	0.1	$	41.7	$	167.3

	December 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.4	$	24.0	$	11.4	$	—
Equity securities	22.7		22.7		—		—
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	58.2	$	46.8	$	11.4	$	—
Liabilities:
Deferred compensation liabilities	$	42.7	$	—	$	42.7	$	—
Contingent consideration and acquired contingent liabilities	246.4		—		—		246.4
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	289.2	$	0.1	$	42.7	$	246.4

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities

The following table summarizes the fiscal 2018 activity for contingent consideration:

Balance at December 29, 2017	$	246.4
Disposal of business	(12.1		)
Payments	(37.0		)
Accretion expense	3.3
Fair value adjustments	(33.3		)
Balance at September 28, 2018	$	167.3

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's debt, excluding capital leases, as of the end of each period:

	September 28, 2018				December 29, 2017
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1
3.50% notes due April 2018	$	—	$	—	$	300.0	$	299.1
4.875% notes due April 2020	700.0		694.7		700.0		675.2
Variable-rate receivable securitization due July 2020	225.0		225.0		200.0		200.0
5.75% notes due August 2022	884.0		815.9		884.0		804.8
4.75% notes due April 2023	500.2		427.7		526.5		412.4
5.625% notes due October 2023	731.4		648.6		738.0		628.8
5.50% notes due April 2025	692.1		583.9		692.1		564.5
Revolving credit facility	300.0		300.0		900.0		900.0
Level 2
9.50% debentures due May 2022	10.4		11.0		10.4		10.9
8.00% debentures due March 2023	4.4		4.5		4.4		4.4
Term loan due September 2024	1,613.8		1,605.5		1,851.2		1,848.7
Term loan due February 2025	597.0		596.8		—		—
Level 3
ACOA loan due December 2028	1.8		1.8		—		—
Total debt	$	6,260.1	$	5,915.4	$	6,806.6	$	6,348.8

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:

	Three Months Ended				Nine Months Ended
	September 28, 2018		September 29, 2017		September 28, 2018		September 29, 2017
CuraScript, Inc.	44.9	%	55.2	%	46.1	%	55.7	%

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:

	September 28, 2018		December 29, 2017
CuraScript, Inc.	30.8	%	33.8	%

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:

	Three Months Ended				Nine Months Ended
	September 28, 2018		September 29, 2017		September 28, 2018		September 29, 2017
H.P. Acthar Gel	45.3	%	51.4	%	44.8	%	51.1	%
Inomax	20.8	%	20.9	%	21.9	%	21.6	%
Ofirmev	13.6	%	12.6	%	13.8	%	12.8	%